Combination therapies of HDAC inhibitors and PD-1 inhibitors
Provided herein are combinations that include an HDACi and a PD-1 inhibitor that are useful for treating cancer, including reducing and/or preventing cancer metastasis. The combination is also useful for treating cancer that has been previously treated with a PD-L1 inhibitor.
1. A method for treating melanoma in a subject, comprising administering to said subject a therapeutically effective amount of a compound of the following formula:
in combination with nivolumab, wherein the subject has been treated with a PD-L1 checkpoint inhibitor.
2. The method of claim 1 , wherein the compound is administered at an amount of about 30 mg BIW.
3. The method of claim 1 , wherein nivolumab is administered as an intravenous infusion over about 30 minutes.
4. The method of claim 1 , wherein the melanoma is Stage II, III or IV melanoma.
5. The method of claim 1 , wherein the melanoma is resistant/refractory melanoma.
6. The method of claim 1 , wherein the melanoma is metastatic.